PHARMAC has approved funding for two new medicines with substantial health benefits for around 53,000 New Zealanders
with type 2 diabetes.
People with high-risk type 2 diabetes, who meet the funding criteria, will be able to access funded empagliflozin (with
or without metformin) from 1 February 2021. They will also be able to get funded dulaglutide once it has Medsafe
approval.
“People with diabetes, their whānau and health professionals told us that there is a need for these effective medicines
to be funded to help manage the growing health problem of type 2 diabetes in Aotearoa,” says PHARMAC’s chief executive
Sarah Fitt.
Evidence suggests these medicines do more than just reduce sugar levels in people with high-risk type 2 diabetes. They
can also help manage type 2 diabetes-related complications like kidney and heart disease in people who are at high risk
of these complications.
“We had originally proposed to fund empagliflozin (with and without metformin) from 1 December 2020, however we received
a substantial amount of consultation feedback that took us some time to work through. After carefully considering the
consultation feedback we made some changes to the Special Authority criteria we originally proposed.”
The changes to the criteria aim to make sure that people with type 2 diabetes who are at a high risk of heart and kidney
complications can access these treatments.
“We have also made the decision to specifically name Māori and Pacific ethnicities within the funding criteria. This is
the first time we have included this wording in Special Authority criteria. This is an intentional move to proactively
promote equity of access to these treatments for population groups who are at high risk of complications of type 2
diabetes and for whom there is direct evidence of inequities in access to medicines. We would like to thank the people
and organisations who contributed important feedback that supported this decision,” says Ms Fitt.
“We know that funding medicines does not in itself address many of the barriers to access that people face. There are
lots of structural issues in the health system that PHARMAC cannot address by itself with this funding decision. We
acknowledge that health inequities are unable to be addressed by medicines alone, and that these medicines are focussed
on treatment, rather than prevention but we also know that PHARMAC does have a role to play.
PHARMAC is committed to continuing our work to fund more medicines for more people, delivering the best possible health
outcomes for New Zealanders from within our fixed budget. The gross cost to the combined pharmaceutical budget for these
two medicines is estimated to be roughly $125 million over 5 years.